Home Cart Sign in  
Chemical Structure| 670220-88-9 Chemical Structure| 670220-88-9

Structure of Crenolanib
CAS No.: 670220-88-9

Chemical Structure| 670220-88-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

Synonyms: CP-868596; CP 868,596; ARO 002

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Crenolanib

CAS No. :670220-88-9
Formula : C26H29N5O2
M.W : 443.54
SMILES Code : NC1CCN(C2=C3N=C(N4C=NC5=CC(OCC6(C)COC6)=CC=C45)C=CC3=CC=C2)CC1
Synonyms :
CP-868596; CP 868,596; ARO 002
MDL No. :MFCD21609260
InChI Key :DYNHJHQFHQTFTP-UHFFFAOYSA-N
Pubchem ID :10366136

Safety of Crenolanib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Crenolanib

RTK

Isoform Comparison

Biological Activity

Target
  • PDGFRβ

    PDGFRβ, Kd:3.2 nM

  • PDGFRα

    PDGFRα, Kd:2.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary human hepatic stellate cells (HSC) 1μM To evaluate the inhibitory effect of Crenolanib on PDGF-BB-induced hepatic stellate cell proliferation PMC6876711
MOLM-13/sor cells 50 nM 24 h Crenolanib induced apoptosis in MOLM-13/sor cells by inhibiting FLT3-ITD and Axl signaling pathways, activating GSK3β and downregulating Mcl-1. PMC9899255
hepatic stellate cells (HSC) 0.1 µM 72 h Crenolanib significantly inhibited PDGF-BB-mediated HSC proliferation PMC8067177
hepatic stellate cells (HSC) 1 µM 7 days Crenolanib treatment induced polygonal cell morphology and lipid accumulation in HSC PMC8067177
mouse mammary fibroblasts (MMFs) 1 μM 24 h Inhibition of PDGFRα-D842V mutation significantly diminished Has1 expression in the PDGFRαactivated MMFs, but did not affect Col1a1, Loxl1 and Mmp3. PMC5440288
Human brain microvascular ECs 5 nM To study the inhibitory effect of Crenolanib on GBM endothelial cells, results showed that combined use with VEGFR inhibitor Ki8751 inhibited endothelial cell proliferation. PMC6110798
Healthy control and systemic sclerosis (SSc) dermal fibroblasts 100 nM 24 h To investigate the effect of Crenolanib on periostin, CCN2, and type I collagen expression in healthy control and SSc dermal fibroblasts. Results showed that Crenolanib significantly reduced periostin and CCN2 protein expression, but had only modest inhibition on type I collagen. PMC5560111
Healthy control and systemic sclerosis (SSc) dermal fibroblasts 100 nM 30 min To investigate the effect of Crenolanib on ERK1/2 and Akt phosphorylation in healthy control and SSc dermal fibroblasts. Results showed that Crenolanib effectively inhibited PDGFAA and PDGFBB-induced ERK1/2 and Akt phosphorylation. PMC5560111

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PDGFR αK mosaic mutant mice Intraperitoneal injection 15mg/kg Once daily for 7 days Crenolanib significantly increased adipogenesis, further supporting the conclusion that PDGFR αK does not erase adipogenic potential. PMC7214206
NOD-SCID mice MOLM-13/sor xenograft model Oral 10 mg/kg Once daily for 12 days Crenolanib alone was not effective in the MOLM-13/sor xenograft model, and the combination with HHT did not show improvement. PMC9899255
rats thioacetamide (TAA)-induced liver fibrosis model via drinking water 0.05 mg/L for 2 weeks Crenolanib significantly improved recovery from TAA-induced liver fibrosis PMC8067177
Mice RCAS transgenic GBM model Peritoneal injection 50 mg/kg Not specified To study the inhibitory effect of Crenolanib on GBM tumor growth, results showed that combined use with Ki8751 significantly prolonged mouse survival and inhibited tumor growth. PMC6110798
Mice Ang II-induced skin and heart fibrosis model Intraperitoneal injection 15 mg/kg Once daily for 2 weeks To evaluate the therapeutic effects of Crenolanib in the Ang II-induced skin and heart fibrosis model. Results showed that Crenolanib significantly reduced skin and heart fibrosis. PMC5560111

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01393912 Diffuse Intrinsic Pontine Glio... More >>ma|Progressive or Refractory High-Grade Glioma Less << PHASE1 COMPLETED 2025-10-16 St. Jude Children's Research H... More >>ospital, Memphis, Tennessee, 38105, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.25mL

0.45mL

0.23mL

11.27mL

2.25mL

1.13mL

22.55mL

4.51mL

2.25mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories